DaVita (DVA) Reports Q4: Everything You Need To Know Ahead Of Earnings

StockStory
02-12
DaVita (DVA) Reports Q4: Everything You Need To Know Ahead Of Earnings

Dialysis provider DaVita Inc. (NYSE:DVA) will be announcing earnings results tomorrow after market close. Here’s what to look for.

DaVita beat analysts’ revenue expectations by 0.5% last quarter, reporting revenues of $3.26 billion, up 4.6% year on year. It was a slower quarter for the company, with a miss of analysts’ EPS estimates.

Is DaVita a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting DaVita’s revenue to grow 3.8% year on year to $3.27 billion, slowing from the 7.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.15 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. DaVita has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average.

Looking at DaVita’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Encompass Health delivered year-on-year revenue growth of 12.7%, beating analysts’ expectations by 1.8%, and Centene reported revenues up 3.4%, topping estimates by 4.4%. Encompass Health traded up 1.3% following the results while Centene was down 6.3%.

Read our full analysis of Encompass Health’s results here and Centene’s results here.

Investors in the healthcare providers & services segment have had steady hands going into earnings, with share prices flat over the last month. DaVita is up 6.3% during the same time and is heading into earnings with an average analyst price target of $159.48 (compared to the current share price of $172.25).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10